349-01-9

Basic information

• Product Name: 2,4-DINITRO-5-FLUOROTOLUENE
• Synonyms: 2,4-DINITRO-5-FLUOROTOLUENE;1-fluoro-5-methyl-2,4-dinitrobenzene;2,4-Dinitro-5-fluorotoluene 99%;2,4-Dinitro-5-fluorotoluene99%;5-FLUORO-2,4-DINITROTOLUENE;2,4-Dinitro-5-fluorotolene;2,4-Dinitro-1-fluoro-5-methylbenzene;2,4-Dinitro-5-methylfluorobenzene
• CAS NO: 349-01-9
• Molecular Formula: C₇H₅FN₂O₄
• Molecular Weight: 200.12
• Product Categories: Halogen toluene
• Mol File: 349-01-9.mol

Chemical Properties

• Melting Point: 82°C
• Boiling Point: 319 °C at 760 mmHg
• Flash Point: 146.8 °C
• Appearance: /
• Density: 1.497 g/cm³
• Vapor Pressure: 0.000649mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: 2,4-DINITRO-5-FLUOROTOLUENE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DINITRO-5-FLUOROTOLUENE(349-01-9)
• EPA Substance Registry System: 2,4-DINITRO-5-FLUOROTOLUENE(349-01-9)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 36/37/39-45
• Hazardous Substances Data: 349-01-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2,4-DINITRO-5-FLUOROTOLUENE is used as an intermediate in the manufacturing of dyes and pigments, contributing to the development of a wide range of colorants for various applications, including textiles, plastics, and paints.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 2,4-DINITRO-5-FLUOROTOLUENE is utilized as a key intermediate in the synthesis of various medicinal compounds, playing a crucial role in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
As a building block in organic synthesis, 2,4-DINITRO-5-FLUOROTOLUENE is employed in the preparation of a diverse array of organic compounds, enabling the creation of novel molecules with potential applications in various fields.
Safety Precautions:
Due to its hazardous nature, 2,4-DINITRO-5-FLUOROTOLUENE may cause irritation to the eyes, skin, and respiratory system. It is essential to handle this chemical with care and follow proper safety protocols during storage and use to minimize the risk of exposure and potential harm.

InChI:InChI=1/C7H5FN2O4/c1-4-2-5(8)7(10(13)14)3-6(4)9(11)12/h2-3H,1H3

Upstream product

• 352-70-5 m-Fluorotoluene 

Downstream Products

• 952665-28-0 (E)-2-(5-fluoro-2,4-dinitrophenyl)-N,N-dimethylethenamine 
• 1307309-23-4 O₂-(2,4-dinitro-5-methylphenyl) 1-[(4-ethoxycarbonyl)homopiperazin-1-yl]diazen-1-ium-1,2-diolate 
• 1307309-22-3 O₂-(2,4-dinitrophenyl-5-methyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl] diazen-1-ium-1,2-diolate 
• 3606-21-1 5-methoxy-2,4-dinitrotoluene 
• 121729-10-0 [2-(5-fluoro-2,4-dinitro-phenyl)-vinyl]-dimethyl-amine 
• 1338223-20-3 1-(5-methyl-2.4-dinitro-phenylamino)-3-(3-trifluoromethyl-phenoxy)-propan-2-one O-methyl-oxime 
• 141922-20-5 4-fluoro-6-methyl-benzene-1,3-diamine 
• 110600-91-4 diethyl 5-fluoro-2,4-dinitrobenzoylmalonate 
• 110600-93-6 ethyl 3-cyclopropylamino-2-(5-fluoro-2,4-dinitrobenzoyl)acrylate 
• 110600-95-8 ethyl 3-cyclopropylamino-2-(5-hydroxy-2,4-dinitrobenzoyl)acrylate 
• 110600-92-5 ethyl 5-fluoro-2,4-dinitrobenzoylacetate 
• 393-92-0 5-fluoro-2,4-dinitrobenzoyl chloride 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOUNDS OF 3-(5-SUSTITUTED OXY-2, 4-DINITROPHENYL)-2-OXO-PROPIONIC ACID ESTER, SYNTHESIS AND APPLICATIONS THEREOF

Synthesis of the novel compound 3 (3-(5-substituted Oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester) to make Pyrroloquinoline quinone (PQQ) and using it for pharmaceutical purposes is described. More specifically, this disclosure relates to synthesizing the PQQ in an efficient method by using a novel intermediate Formula 1 resulting in a shorter process and higher yield of PQQ. A unique process to make sodium compound of PQQ using either sodium hydroxide and/or sodium carbonate is also shown.

COMPOUNDS OF '3-(5-SUSTITUTED OXY-2,4-DINITRO-PHENYL)-2-OXO-PROPIONIC ACID ESTER', PROCESS AND APPLICATIONS THEREOF

The present disclosure relates to compounds of Formula (I) and process of obtaining the same. Said compounds of Formula (I) is employed in the syntheses of pyrroloquinoline quinone (PQQ), 4,5-dioxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid 2-allyl ester, 5-ethoxy-5-hydroxy-4-oxo-4,5-dihydro-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, 5- hydroxy-6-(1,1,4-trioxo-1 lambda* 6*-1,2, 5 -thiadiazolidin-2-yl)-1H-indole-2-carboxylic acid and its pharmaceutically acceptable salts. Said syntheses of compounds via. compounds of Formula (I) as intermediates employ minimum number of steps resulting in a shorter process and has improved efficiency along with many other advantages.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Quinazoline derivatives and therapeutic use thereof

Quinazoline derivatives represented by the general formula pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for using the compounds for treatment of hyperproliferative disorders are also described.

5-halogen-2,4-Bis (alkylamino)-1-alkylbenzenes and hair dye compositions containing same

The composition for the oxidative dyeing of hair contains at least one coupler of the general formula STR1 where R is a straight-chain or branched C1 - to C4 -alkyl group, X is chlorine or fluorine, and R1 is a straight-ch

Process for the production of 5-alkoxy-2,4-dinitro-alkylbenzenes

Process for producing 5-alkoxy-2,4-dinitroalkylbenzenes of the general formula (I) STR1 R1 =C1 to C4 alkyl; R=C1 to C6 alkyl group, C2 to C4 hydroxyalkyl, C3 to C4 dihydroxyalkyl, in which a 3-fluoroalkylbenzene is nitrated and the obtained 2,4-dinitro-5-fluoroalkylbenzene is then reacted with a suitable alcohol at -5° C. to +25° C. with the addition of sodium hydroxide or potassium hydroxide.

Composition for the oxidative dyeing of hair and new 5-halogen-2,4-diamino alkylbenzenes

The composition for the oxidative dyeing of hair contains at least one coupler substance of the formula STR1 where R is a straight-chain or branched C1 - to C4 -alkyl group and X is fluorine or bromine, and new 5-halogen-2,4-diaminoa